Argenica Therapeutics Ltd Cash Flow Conversion Efficiency

Latest as of December 2025: -1.602x

Argenica Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Argenica Therapeutics Ltd (AGN) has a cash flow conversion efficiency ratio of -1.602x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.51 Million ≈ $-3.90 Million USD) by net assets (AU$3.44 Million ≈ $2.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Argenica Therapeutics Ltd (2019–2024)

Cash flow conversion efficiency of Argenica Therapeutics Ltd from 2019 to 2024. This chart illustrates how Argenica Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AGN live share price for real-time trading data and today's change.

Argenica Therapeutics Ltd Cash Flow Conversion Ratio Explained

Argenica Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Argenica Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Argenica Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see Argenica Therapeutics Ltd (AGN) total market value for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
YLI Holdings Bhd KLSE:7014	-0.016x
COSCIENS Biopharma Inc. NASDAQ:CSCI	-0.627x
Goyal Aluminiums Limited NSE:GOYALALUM	0.036x
Green Earth Group N.V. AS:HWK	0.038x
HEBEI CONSTR.GRP CORP YC1 F:H9D	N/A
ENERGY S.P.A. F:S2I	N/A
Nubeva Technologies Ltd V:NBVA	-0.079x
LDT Inc KQ:096870	0.027x

Annual Cash Flow Conversion Efficiency for Argenica Therapeutics Ltd (2019–2024)

The table below shows the annual cash flow conversion efficiency of Argenica Therapeutics Ltd from 2019 to 2024. Review AGN free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$7.24 Million ≈ $5.12 Million	AU$-5.70 Million ≈ $-4.04 Million	-0.788x	-117.29%
2023-12-31	AU$13.95 Million ≈ $9.87 Million	AU$-5.06 Million ≈ $-3.58 Million	-0.363x	+15.74%
2022-12-31	AU$7.67 Million ≈ $5.42 Million	AU$-3.30 Million ≈ $-2.34 Million	-0.430x	-6.38%
2021-12-31	AU$8.31 Million ≈ $5.88 Million	AU$-3.36 Million ≈ $-2.38 Million	-0.405x	-164.77%
2020-12-31	AU$6.85 Million ≈ $4.84 Million	AU$-1.05 Million ≈ $-740.40K	-0.153x	+95.22%
2019-12-31	AU$18.40K ≈ $13.02K	AU$-58.82K ≈ $-41.62K	-3.197x	--

About Argenica Therapeutics Ltd

AU:AGN Australia Biotechnology

Market Cap

$8.63 Million

AU$12.20 Million AUD

Market Cap Rank

#27289 Global

#1307 in Australia

Share Price

AU$0.10

Change (1 day)

-5.00%

52-Week Range

AU$0.09 - AU$0.34

All Time High

AU$0.99